Compare Medpace Holdings Inc (MEDP) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nutanix Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Nutanix Inc trades at $74.59 (market cap $19.78B). The key difference: Nutanix Inc is the larger of the two by market cap, and Nutanix Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Nutanix Inc for 17 Days on average.
| MEDP | NTNX | |
|---|---|---|
Market Cap | $16.82B | $19.78B |
Volume | 223,093 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $630.19 | $73.42 |
52-Week Low | $393.42 | $34.41 |
Typical Hold Time | 14 Days | 17 Days |
Enterprise Value | $16.44B | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Nutanix (NTNX) trades at $74.63, up 1.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.54B in 2025 and a net income margin of 52.81% in 2026, supported by leadership recognition in Gartner Magic Quadrant reports (GlobeNewsWire, 2026-09-16).
Outlook remains positive with a consensus price target of $76.11, though high valuation ratios like EV/EBITDA of 46.22 and an overbought RSI near 89.09 pose risks. Growth drivers include external storage and AI initiatives, but investor caution is warranted due to competitive pressures and supply-chain constraints noted in recent news (MarketBeat, 2026-09-14).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
